Ascletis Pharma (China) Co. Ltd. has reported new gastric inhibitory polypeptide receptor (GIPR) and glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of diabetes, obesity, Alzheimer’s disease, osteoporosis, psoriasis, sleep apnea, inflammatory bowel and cardiovascular disorders, among others.